Skip to main content
Caplight Logo









Nobilis Therapeutics

Nobilis Therapeutics

Private
Portland, OregonHealthcare & Life Scienceshttps://www.nobilistx.com/

Last Round

Grant

Sep 30, 2021

Total Funding Raised

$831,992

Momentum

Top 50%

of companies Caplight tracks

Company Overview

Nobilis Therapeutics is a biotechnology company that develops inhalation-based therapeutics using inert gas mixtures and portable delivery devices for the treatment of psychiatric and neurodegenerative disorders.

Sector

Healthcare & Life Sciences

Verticals

Biotechnology, Medical Devices, Mental Health, Clinical Trials

Business Model

B2B

Customer Profile

Services & Consulting

AI Layer

Non-AI

Keywords

biopharmaceuticalcentral nervous systemCNSinhalation therapyxenon therapydrug-device combinationmedical devicePTSD treatmentanxiety treatmentnoble gas therapyclinical trialsneurological disordersbiohackingmental health tech

Historical Pricing

Historical view of private secondary pricing and transaction trends.

Unlock Pricing Charts

Sign up to view complete historical pricing and secondary transactions.

Caplight Momentum Score

Proprietary index based on bid/ask volume and sentiment.

View Momentum History

Track how buyer interest and sentiment changes over time.

Nobilis Therapeutics Comparables

Compare Nobilis Therapeutics with similar companies based on industry and business-model similarity.

Nobilis Therapeutics comparables — related companies by embedding similarity
CompanySimilarityMarket Cap
Rheos Medical Corp.
79%
GH Research
77%
Nexalis Therapeutics Limited
77%

Nobilis Therapeutics Funding Rounds

Historical fundraising activity

Data table
RoundDateAmount RaisedValuationInvestorsSources
GrantSep 30, 2021
DebtFeb 15, 2018
SeedSep 7, 2016

Nobilis Therapeutics Investors

Notable investors and investment history

Nobilis Therapeutics investors
InvestorRounds
National Institutes of Health (NIH)Grant

Market signals

Structured signals derived from secondary market and firmographic data.

  • Jul 26, 2026

    Monthly visitors grew 425% MoM, from 274 to 1.4K.

  • Feb 15, 2018

    $500K debt round completed.

Nobilis Therapeutics Filings

Explore SEC and related filing metadata, where available.

Nobilis Therapeutics filings preview — column headings only; records require access
TypeDateAmount OfferedAmount SoldFilingPagesDownload

Filing documents are not displayed on this public page. Request access to learn about available coverage.

Request access

Frequently Asked Questions

Common questions about Nobilis Therapeutics's valuation, stock price, and market status.

Is Nobilis Therapeutics a public or private company?

Nobilis Therapeutics is a private company.

What is the current stock price of Nobilis Therapeutics?

Nobilis Therapeutics is a private company, so its shares have no public market price. Caplight tracks Nobilis Therapeutics's secondary market activity and provides MarketPrice™ estimates of its share price to Caplight users.

How much is Nobilis Therapeutics worth (valuation)?

Valuation information for Nobilis Therapeutics is not publicly available.

Can I buy Nobilis Therapeutics stock?

Nobilis Therapeutics shares may be available on secondary markets subject to transfer restrictions. Caplight facilitates secondary market transactions for accredited investors.

When was Nobilis Therapeutics's last funding round?

Nobilis Therapeutics's most recent funding round was Grant on September 30, 2021.

Who are the main investors in Nobilis Therapeutics?

Key investors in Nobilis Therapeutics include National Institutes of Health (NIH).

Will Nobilis Therapeutics IPO soon?

No public IPO plans have been announced for Nobilis Therapeutics.

How can I track Nobilis Therapeutics secondary market activity?

Caplight tracks bids, offers, and trades in Nobilis Therapeutics's shares on secondary markets.

Firmographic Details

HeadquartersPortland, Oregon
Employee Range1
Year Founded2016
Last FundingSep 30, 2021

Institutional Data Access

Join leading institutional investors using Caplight to access private market data, discover pricing, and execute secondary block trades.

Requires verified institutional or accredited status.

See something wrong or outdated?